News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Conference News EAS 2023 Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH Michael O'Riordan May 24, 2023
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level Michael O'Riordan May 24, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2020 Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention Michael O'Riordan October 08, 2020
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News EAS 2019 Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION Michael O'Riordan June 04, 2019
News Conference News EAS 2018 Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics Yael L. Maxwell May 16, 2018
News Conference News EAS 2018 ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran Yael L. Maxwell May 14, 2018
News Conference News EAS 2017 FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data Yael L. Maxwell April 26, 2017
News Conference News EAS 2017 Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both Yael L. Maxwell April 25, 2017